Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.

@article{Mross1993RandomizedPI,
  title={Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.},
  author={Klaus G Mross and Chantal Bohn and Lutz Edler and Walter Jonat and Wolfgang Queisser and Else Heidemann and Megan Goebel and Dieter Kurt Hossfeld},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1993},
  volume={4 1},
  pages={45-50}
}
BACKGROUND Anthracyclines are the most active cytostatic agents in patients with metastatic breast cancer. Drug resistance and dose intensity are relevant issues in the treatment of cancer. METHODS A randomized phase II study in 51 patients with advanced progressive metastatic breast cancer was performed. Twenty-six were treated with epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days combined with a daily dose of 480 mg verapamil (VPL) orally administered one day before… CONTINUE READING
14 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…